LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup
LivaNova (NASDAQ:LIVN) demonstrates strong growth fundamentals with consistent EPS and revenue expansion, coupled with high profitability metrics. The stock also presents a promising technical setup, scoring 10 out of 10 in ChartMill's technical rating, indicating a potential breakout from a resistance zone. This combination of robust growth and a favorable technical chart pattern suggests a potential investment opportunity, though investors should be mindful of the company's health rating and debt ratios.
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE
Bank of America Corp DE reduced its stake in LivaNova PLC (NASDAQ:LIVN) by 30.6% in the first quarter, selling 235,233 shares but still retaining 533,017 shares valued at $33.9 million. Institutional investors now own 97.64% of the company's stock. LivaNova recently surpassed earnings expectations, reporting $1.26 per share on revenues of $390.6 million, an increase of 10.8% year-over-year.
LivaNova (LIVN) executive exercises 12,692 SARs and disposes shares
LivaNova PLC's Chief Innovation Officer, Ahmet Tezel, exercised 12,692 Stock Appreciation Rights (SARs) at a base price of $52.68 per share. Concurrently, 8,589 shares were withheld to cover the SARs base price, 1,428 shares for tax liability, and 2,675 shares were sold on the open market at a weighted-average price of $77.7355. After these transactions, Tezel holds 12,691 SARs and 6,090 ordinary shares.
LivaNova (LIVN) Q2 2026 Earnings Call Transcript
LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to $4.30-$4.40, citing improved market share, Essenz upgrade cycles, and favorable Medicare reimbursement. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and provided updates on its innovation pipeline, including next-generation oxygenators and advancements in its Obstructive Sleep Apnea program.
LivaNova PLC (LIVN) employee stock rights lead to 2,675-share sale
LivaNova PLC has reported a planned sale of 2,675 shares of common stock, stemming from the exercise of employee stock appreciation rights. The transaction, valued at $209,942.40, is scheduled for August 11, 2026, and will be executed through Merrill Lynch as a broker-assisted cashless exercise on NASDAQ. This Form 144 filing provides transparency regarding the upcoming sale of employee-held shares.
Price-Driven Insight from (LIVN) for Rule-Based Strategy
This article provides a price-driven insight into Livanova Plc (NASDAQ: LIVN) for rule-based trading strategies. It highlights weak near-term sentiment challenging long-term strength, with support being tested. The analysis identifies an exceptional 28.8:1 risk-reward setup targeting an 8.4% gain against 0.3% risk, and outlines institutional trading strategies (Position, Momentum Breakout, Risk Hedging) based on AI models across different time horizons.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant swing back to profitability in Q2 2026, with sales of US$390.59 million and net income of US$108.57 million. This turnaround, bolstered by the PMA approval of its aura6000 system, suggests a stronger earnings profile and potential for future growth in neuromodulation and cardiopulmonary demand. However, the company still faces risks from pricing pressure, reimbursement limits, and high R&D spending.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This performance, along with the recent PMA approval of its aura6000 system for obstructive sleep apnea, strengthens its investment narrative, though risks like pricing pressure and R&D spending persist. Despite the positive earnings, the stock was down 7.6%, prompting an exploration of how these results reshape its financial outlook.
LivaNova (LIVN) Is Down 7.6% After Swinging Back To Profitability In Q2 2026 - What's Changed
LivaNova (LIVN) reported a significant turnaround in Q2 2026, swinging back to profitability with US$108.57 million in net income and US$390.59 million in sales. This improvement was driven by strong first-half sales of US$752.85 million and a shift from a prior-year loss, strengthening the company's investment narrative. The company's recent PMA approval for the aura6000 system for obstructive sleep apnea is expected to diversify its revenue streams, though potential challenges like pricing pressure and R&D costs remain.
Price to earnings forward of LivaNova Plc – FWB:LIA
This article provides a brief overview of LivaNova Plc's forward price-to-earnings ratio on the Frankfurt Stock Exchange (FWB:LIA). It highlights that the market is currently closed with no trades, and the content is primarily focused on the financial data of the company. The page also offers various tools and resources available on the TradingView platform.
LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...
LivaNova PLC (LIVN) reported record revenue of $391 million and adjusted EPS of $1.26 for Q2 2026, driven by strong growth in both Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted EPS guidance to $4.30-$4.40, reflecting robust operational performance. Despite these positive results, the company lowered its free cash flow guidance due to increased capital spending and an OSA program timeline delay.
LivaNova PLC Stock 12‑Month Price Target Raised to $88.78, Implies 4% Upside
LivaNova PLC (LIVN) has seen its average 12-month price target increased from $86.78 to $88.78 by 9 analysts, with individual forecasts ranging from $75 to $95. This new target suggests a potential upside of approximately 4% from its closing price on August 4. The consensus rating from 11 analysts remains a "Buy," with 8 Buy recommendations, 2 Holds, and 1 Sell.
FMR LLC (LIVN) discloses 5.8% LivaNova stake in Schedule 13G filing
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 5.8% in LivaNova PLC (LIVN) common stock, amounting to 3,210,395.27 shares as of June 30, 2026. Both FMR LLC and Abigail P. Johnson reported this stake, with FMR LLC holding sole voting power over most shares and both entities having sole dispositive power. This filing indicates a passive investment, not intended to influence company control.
LivaNova Plans for Early 2027 Launch of Aura6000 for Obstructive Sleep Apnea
LivaNova, a medical-device firm, plans an early 2027 launch for its Aura6000 device designed to treat obstructive sleep apnea. The company employs an innovation strategy focused on differentiated products and strong commercialization through salesforce relationships, similar to larger competitors. This strategy aims to create pricing premiums through meaningful innovation, either internal or augmented by emerging technology acquisitions.
LivaNova PLC 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:LIVN) 2026-08-05
LivaNova PLC (NASDAQ: LIVN) has released its Q2 2026 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.17, and revenue of $390.60 million, a 10.81% year-over-year increase, beating estimates by $10.02 million. This presentation provides details on their financial performance for the quarter.
LivaNova (LIVN) Reports Q2 Earnings: What Key Metrics Have to Say
LivaNova (LIVN) reported strong Q2 2026 earnings, with revenue of $390.6 million and EPS of $1.26, surpassing Wall Street expectations. The company exceeded consensus estimates for net sales in Neuromodulation, Cardiopulmonary, and Other segments. Despite the positive results, LivaNova's stock performance over the past month lagged the S&P 500, though it currently holds a Zacks Rank #2 (Buy).
LivaNova plc (LIVN) Tops Q2 EPS by 17c ; Offers Guidance
LivaNova plc (LIVN) exceeded analyst expectations for its Q2 earnings, reporting an EPS of $1.26 against an estimated $1.09, and revenue of $390.6 million compared to the $380.57 million consensus. The company also provided optimistic guidance for FY2026 EPS, projecting $4.30-$4.40, which is above the analyst consensus of $4.25. The stock price showed a significant decrease of 10.82% on the day.
Earnings Flash (LIVN) LivaNova PLC Reports Q2 Revenue $390.6M, vs. FactSet Est of $380.5M
LivaNova PLC (LIVN) announced Q2 revenue of $390.6 million, surpassing the FactSet estimate of $380.5 million. The company also reported Q2 adjusted EPS of $1.26 per share, exceeding the FactSet estimate of $1.09, and raised its fiscal 2026 adjusted EPS outlook to a range of $4.30 to $4.40, against an earlier FactSet estimate of $4.25.
LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova PLC reported strong second-quarter 2026 results, with reported revenue growth of 10.8% and constant-currency growth of 9.8%. The company raised its full-year 2026 revenue and adjusted diluted earnings per share guidance, citing sustained performance in its Cardiopulmonary and Neuromodulation businesses. LivaNova also announced a long-term agreement with Thermo Fisher Scientific to enhance oxygenator component supply, aiming to meet unmet customer demand.
LivaNova PLC stock hits 52-week high at 85.28 USD
LivaNova PLC (LIVN) stock reached a new 52-week high of $85.28, reflecting a 92.84% one-year total return and a market capitalization of $4.68 billion. Despite this surge, InvestingPro analysis suggests the stock is still slightly undervalued. The company also announced strategic leadership changes and promising data for its sleep apnea therapy.
LivaNova PLC stock hits 52-week high at 85.28 USD By Investing.com
LivaNova PLC stock reached a new 52-week high of $85.28, reflecting a significant upward trend with a 92.84% 1-year total return. The company, with a market capitalization of $4.68 billion, is considered slightly undervalued according to InvestingPro, which also highlights its low P/E ratio relative to near-term earnings growth. Recent strategic developments include new analyst coverage, promising clinical data for its sleep apnea therapy, and changes to its board and executive team.
(LIVN) Price Dynamics and Execution-Aware Positioning
This article analyzes Livanova Plc (NASDAQ: LIVN) price dynamics, identifying a near-term strong sentiment transitioning to mid-term neutrality and long-term positive bias. It highlights an exceptional 26.2:1 risk-reward short setup and provides institutional trading strategies for different risk profiles, including position trading, momentum breakout, and risk hedging, alongside multi-timeframe signal analysis.
LivaNova PLC (LIVN) Financial Health: Profitability & Balance Sheet Analysis
LivaNova PLC (LIVN) has a robust financial status with a current financial score of 7.86, ranking 54 out of 199 in its industry. The company reported a significant year-over-year revenue increase of 14.33% and a net profit increase of 106.81%, demonstrating high operating efficiency. Key financial metrics like cash and cash equivalents, total assets, and cash flow from operating activities contribute to its strong performance.
LivaNova PLC (LIVN) Institutional Confidence
This article analyzes the institutional confidence in LivaNova PLC (LIVN), reporting its current institutional shareholding score as 10.00, which ranks 1st in the Healthcare Equipment & Supplies industry. Institutional shareholding has increased by 3.56% quarter-over-quarter, with HOTCHKIS & WILEY identified as the largest institutional shareholder. The report also lists other major institutional shareholders and their recent changes in holdings.
LivaNova PLC (LIVN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for LivaNova PLC (LIVN), noting its current valuation score is 6.28, ranking 184 out of 199 in its industry. The company's P/E ratio stands at 41.18, significantly above its recent low. However, key P/B, P/S, and P/CF data are not yet disclosed.
LivaNova PLC (LIVN) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for LivaNova PLC (LIVN), detailing its volatility, financial risk, and investment risk. LIVN has a current risk assessment score of 7.91, ranking 27th in the Healthcare Equipment & Supplies industry, with a beta of 0.87 indicating less volatility than the market. The report includes various metrics such as VaR, maximum drawdown, daily returns, Sharpe Ratio, skewness, and liquidity measures to give a comprehensive overview of the stock's risk profile.
LIVN|LivaNova PLC|Price:80.640|Chg%:+2.450
LivaNova PLC (LIVN) has relatively healthy fundamentals and high growth potential, though its performance has turned to a loss from a profit. The company is considered fairly valued within the Healthcare Equipment & Supplies industry. Institutional ownership is high, and analysts have a "Buy" rating with a target price of 84.93, suggesting an upside.
LivaNova PLC (LIVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of LivaNova PLC (LIVN), detailing its price momentum score, current trading range, and indicators. It includes a breakdown of various technical indicators like MACD, RSI, and moving averages, offering insights into potential buy or sell signals. The analysis also features an FAQ section clarifying technical ratings and moving averages.
LivaNova PLC (LIVN) Balance Sheet
This article provides a detailed balance sheet for LivaNova PLC (LIVN), offering both quarterly and annual financial data. It allows users to analyze the company's financial health, fundamentals, and key ratios related to liquidity, leverage, and return on equity. The page also includes FAQs defining important balance sheet metrics and providing quick answers about LIVN's cash, liabilities, assets, and shareholders' equity.
LivaNova PLC (LIVN) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of LivaNova PLC (LIVN) focusing on its dividend history. It states that the company has not distributed any dividends over the past five years. Key financial figures like market cap and P/E ratio are also presented.
LivaNova PLC (LIVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of LivaNova PLC's (LIVN) revenue breakdown, focusing on regional contributions. As of the stated update, the company has not disclosed detailed business segment data. The revenue figures show that the United States is the largest contributor, followed by the Rest of World and Europe.
LIVN|LivaNova PLC|Price:78.190|Chg%:-0.420
LivaNova PLC (LIVN) is a medical technology company specializing in cardiopulmonary and neuromodulation products, including heart-lung machines and VNS Therapy Systems for epilepsy. The article provides company details, financial overview, executive shareholdings, and institutional ownership data for LivaNova PLC. The stock closed at $78.190, down 0.53%, with a market cap of $4.29 billion.
LivaNova PLC (LIVN) Earnings Forecast: Future EPS & Revenue Growth Estimates
LivaNova PLC (LIVN) has an earnings forecast score of 8.18, placing it 58th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $67.50, with most recommending a "Buy" trend. The company's expected revenue for the next quarter is $380.76 million, and its EPS for the previous quarter was $0.57, with the next quarter's EPS expected at $1.10.
LivaNova PLC Revenue Breakdown – NASDAQ:LIVN
LivaNova PLC (NASDAQ:LIVN) generated 1.39 billion USD in revenue last year, with its Cardiopulmonary segment being the top performer, contributing 785.38 million USD. The United States was the company's largest regional contributor, accounting for 739.57 million USD. The article provides a high-level overview of the company's revenue breakdown by segment and country.
LIVN6033156 Bond Risk Profile
This article provides a risk profile for the LivaNova PLC 2.5% 15-MAR-2029 bond, identified as LIVN6033156. It lists key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate reliability. The platform also offers access to exclusive analyst ratings for bonds.
LIVN6033156 Bond Profile — Key Metrics
This article provides a detailed profile of the LivaNova PLC (LIVN6033156) bond, including its key metrics such as a 2.5% coupon rate and a maturity date of March 15, 2029. It highlights that LivaNova Plc is a global medical technology company headquartered in London, specializing in cardiopulmonary, neuromodulation, and advanced circulatory support segments. The bond has an outstanding amount of $345 million USD and a face value of $1,000 USD.
LIVN6033156 Bond Coupon Profile — Rate & Payments
This article provides a bond coupon profile for LIVN6033156, a LivaNova PLC bond with a 2.5% interest rate maturing on March 15, 2029. It details the current coupon rate, notes that the next payment is scheduled for September 15, 2026, and offers an overview of interest payment information. The piece emphasizes the importance of coupon data for insights into bond performance.
(LIVN) as a Liquidity Pulse for Institutional Tactics
This article analyzes Livanova Plc (NASDAQ: LIVN) for institutional trading strategies, identifying weak near-term sentiment but strong long-term potential. It provides AI-generated strategies including long, breakout, and short setups, along with multi-timeframe signal analysis indicating support and resistance levels. The analysis aims to offer sophisticated risk management for optimizing positions.
Q1 2020 LivaNova PLC Earnings Call Transcript
This is a transcript of the Q1 2020 Earnings Call for LivaNova PLC, held on April 29, 2020. The call featured Damien McDonald (CEO), Thad Huston (CFO), and Matthew Dodds (SVP of Corporate Development), discussing the company's financial results and forward-looking statements. The full transcript provides detailed insights into their performance and outlook.
LivaNova PLC (BSP:L2IV34) - Valuation Measures & Financial Statistics
This article provides an extensive list of valuation measures and financial statistics for LivaNova PLC (BSP:L2IV34), as tracked by GuruFocus. It details various categories such as operating data, fundamental metrics, valuation ratios, profitability, stock price performance indicators, dividend information, and items from the income statement, balance sheet, and cash flow statement. The page also highlights GuruFocus's detection of 7 medium warning signs for L2IV34 and offers a 7-day free trial to explore this information further.
LIVN Maintains by Mizuho -- Price Target Raised to $95.00
Mizuho analyst Anthony Petrone maintained an Outperform rating for LivaNova (LIVN) and raised the price target to $95.00 from $90.00. This reflects confidence in the company's growth, despite GuruFocus indicating LIVN is currently overvalued with a GF Value™ of $62.61 against a current price of $79.89. The company's GF Score™ is 74/100, showing solid performance across key financial metrics, though insider selling activity has been observed.
LivaNova PLC (LIVN) Shares Fall 4.7% -- GF Value Says Still Overvalued
LivaNova PLC (LIVN) shares fell 4.7% to $79.13, yet GuruFocus's GF Value still assesses the stock as "Modestly Overvalued" with an estimated intrinsic value of $62.60. Despite a current P/E ratio lower than its historical median, insider selling of $0.2 million with no buying activity also raises concerns. The company holds a GF Score of 74/100, reflecting solid financial strength and growth potential but adequate profitability and moderate valuation/momentum.
LivaNova appoints Anne Liddy as chief legal officer
LivaNova has announced the appointment of Anne Liddy as the new chief legal officer. Liddy brings experience from her previous role as global legal head for the cardiovascular, renal, and medical products group at Baxter International, and has held positions at Hillrom and Abbott Laboratories. She will be a member of the executive leadership team, reporting to CEO and Chair, Damien McDonald.
Enterprise value to EBIT forward of LivaNova Plc – SWB:LIA
This article provides financial information for LivaNova Plc (SWB:LIA), specifically focusing on its enterprise value to EBIT forward. The content is presented within the context of TradingView's platform, offering financial data and market insights for the Stuttgart Stock Exchange.
Price to earnings forward of LivaNova Plc – SWB:LIA
This article provides financial information for LivaNova Plc (SWB:LIA), specifically focusing on its Price to Earnings Forward metric. The content, presented by TradingView, is part of a larger financial data service, indicating no specific data points but rather a static page for the company's financial overview. Financial data is provided by ICE Data Services and FactSet, with SEC filings from Quartr.
Price to sales forward of LivaNova PLC – NASDAQ:LIVN
This article provides the "Price to sales forward" metric for LivaNova PLC (NASDAQ: LIVN) on TradingView. It indicates that the market is closed and no trades have occurred for this specific metric. The content is presented within the context of TradingView's financial analysis tools.
LivaNova PLC balances neuromodulation growth with cardiac surgery challenges
LivaNova PLC focuses on expanding its neuromodulation solutions for neurological disorders while maintaining its core presence in cardiac surgery devices. The company balances investments between these two areas, with neuromodulation offering higher growth potential and cardiac surgery providing stable demand despite price pressures. This strategy aims to leverage clinical expertise and address chronic diseases in neurology and cardiology.
(LIVN) as a Liquidity Pulse for Institutional Tactics
This article provides an in-depth AI-driven analysis for Livanova Plc (NASDAQ: LIVN), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines detailed institutional trading strategies, including position trading, momentum breakout, and risk hedging, with specific entry zones, targets, and stop losses. The analysis also features multi-timeframe signal analysis and AI-generated signals to guide investors.
LivaNova Stock Sinks After Key Sleep Trial Fails
LivaNova PLC's stock is falling after its OSPREY clinical trial for the aura6000 sleep apnea device failed to achieve its primary efficacy goal, leading to the study's discontinuation. This setback eliminates a significant growth opportunity for LivaNova and concerns investors about its future product pipeline. Despite the trial failure, the company's strong cash generation and reduced debt provide financial stability to continue investing in its core businesses, though ongoing operational challenges like supply bottlenecks and earnings volatility could impact investor confidence and consistent growth.
Price to book forward of LivaNova PLC – NASDAQ:LIVN
This article provides financial data for LivaNova PLC (NASDAQ: LIVN), specifically its price-to-book forward ratio. It is a brief financial snippet from TradingView, offering current valuation metrics for the company.
